231 related articles for article (PubMed ID: 32869125)
21. Safety of current treatments for paroxysmal nocturnal hemoglobinuria.
Lee SE; Lee JW
Expert Opin Drug Saf; 2021 Feb; 20(2):171-179. PubMed ID: 33249943
[No Abstract] [Full Text] [Related]
22. Predictors for improvement in patient-reported outcomes: post hoc analysis of a phase 3 randomized, open-label study of eculizumab and ravulizumab in complement inhibitor-naive patients with paroxysmal nocturnal hemoglobinuria.
Schrezenmeier H; Kulasekararaj A; Mitchell L; de Latour RP; Devos T; Okamoto S; Wells R; Popoff E; Cheung A; Wang A; Tomazos I; Patel Y; Lee JW
Ann Hematol; 2024 Jan; 103(1):5-15. PubMed ID: 37804344
[TBL] [Abstract][Full Text] [Related]
23. Norm-based comparison of the quality-of-life impact of ravulizumab and eculizumab in paroxysmal nocturnal hemoglobinuria.
Schwartz CE; Stark RB; Borowiec K; Nolte S; Myren KJ
Orphanet J Rare Dis; 2021 Sep; 16(1):389. PubMed ID: 34526067
[TBL] [Abstract][Full Text] [Related]
24. Pharmacological and clinical profile of ravulizumab 100 mg/mL formulation for paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.
Ariceta G
Expert Rev Clin Pharmacol; 2023 May; 16(5):401-410. PubMed ID: 37128905
[TBL] [Abstract][Full Text] [Related]
25. Cost-Utility Analysis of Ravulizumab Compared with Eculizumab in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria.
O'Connell T; Buessing M; Johnson S; Tu L; Thomas SK; Tomazos I
Pharmacoeconomics; 2020 Sep; 38(9):981-994. PubMed ID: 32519233
[TBL] [Abstract][Full Text] [Related]
26. Safety and efficacy of the terminal complement inhibitor eculizumab in Japanese patients with paroxysmal nocturnal hemoglobinuria: the AEGIS clinical trial.
Kanakura Y; Ohyashiki K; Shichishima T; Okamoto S; Ando K; Ninomiya H; Kawaguchi T; Nakao S; Nakakuma H; Nishimura J; Kinoshita T; Bedrosian CL; Valentine ME; Khursigara G; Ozawa K; Omine M
Int J Hematol; 2011 Jan; 93(1):36-46. PubMed ID: 21222185
[TBL] [Abstract][Full Text] [Related]
27. Effects of eculizumab treatment on quality of life in patients with paroxysmal nocturnal hemoglobinuria in Japan.
Ueda Y; Obara N; Yonemura Y; Noji H; Masuko M; Seki Y; Wada K; Matsuda T; Akiyama H; Ikezoe T; Chiba S; Kanda Y; Kawaguchi T; Shichishima T; Nakakuma H; Okamoto S; Nishimura JI; Kanakura Y; Ninomiya H
Int J Hematol; 2018 Jun; 107(6):656-665. PubMed ID: 29383624
[TBL] [Abstract][Full Text] [Related]
28. Changes in Hematologic Lab Measures Observed in Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with C5 Inhibitors, Ravulizumab and Eculizumab: Real-World Evidence from a US Based EMR Network.
Fishman J; Kuranz S; Yeh MM; Brzozowski K; Chen H
Hematol Rep; 2023 Apr; 15(2):266-282. PubMed ID: 37092521
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and Safety of Eculizumab for Paroxysmal Nocturnal Hemoglobinuria: A Systematic Review and Meta-Analysis.
Zhou S; Dong X; Chen C; Ma L; Wu Y; Zhou Y; Cui Y
J Pediatr Hematol Oncol; 2021 Aug; 43(6):203-210. PubMed ID: 33902068
[TBL] [Abstract][Full Text] [Related]
30. Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria.
Brodsky RA; Young NS; Antonioli E; Risitano AM; Schrezenmeier H; Schubert J; Gaya A; Coyle L; de Castro C; Fu CL; Maciejewski JP; Bessler M; Kroon HA; Rother RP; Hillmen P
Blood; 2008 Feb; 111(4):1840-7. PubMed ID: 18055865
[TBL] [Abstract][Full Text] [Related]
31. The burden of illness in patients with paroxysmal nocturnal hemoglobinuria receiving treatment with the C5-inhibitors eculizumab or ravulizumab: results from a US patient survey.
Dingli D; Matos JE; Lehrhaupt K; Krishnan S; Yeh M; Fishman J; Sarda SP; Baver SB
Ann Hematol; 2022 Feb; 101(2):251-263. PubMed ID: 34973099
[TBL] [Abstract][Full Text] [Related]
32. Ravulizumab: a novel C5 inhibitor for the treatment of paroxysmal nocturnal hemoglobinuria.
Stern RM; Connell NT
Ther Adv Hematol; 2019; 10():2040620719874728. PubMed ID: 31534662
[TBL] [Abstract][Full Text] [Related]
33. Clinical benefit of eculizumab in patients with no transfusion history in the International Paroxysmal Nocturnal Haemoglobinuria Registry.
Almeida AM; Bedrosian C; Cole A; Muus P; Schrezenmeier H; Szer J; Rosse WF
Intern Med J; 2017 Sep; 47(9):1026-1034. PubMed ID: 28608499
[TBL] [Abstract][Full Text] [Related]
34. Cost-effectiveness of ravulizumab compared with eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria in the Netherlands.
Quist SW; Postma AJ; Myrén KJ; de Jong LA; Postma MJ
Eur J Health Econ; 2023 Dec; 24(9):1455-1472. PubMed ID: 36633725
[TBL] [Abstract][Full Text] [Related]
35. Pegcetacoplan versus eculizumab in patients with paroxysmal nocturnal haemoglobinuria (PEGASUS): 48-week follow-up of a randomised, open-label, phase 3, active-comparator, controlled trial.
de Latour RP; Szer J; Weitz IC; Röth A; Höchsmann B; Panse J; Usuki K; Griffin M; Kiladjian JJ; de Castro CM; Nishimori H; Ajayi T; Al-Adhami M; Deschatelets P; Francois C; Grossi F; Risitano AM; Hillmen P
Lancet Haematol; 2022 Sep; 9(9):e648-e659. PubMed ID: 36055332
[TBL] [Abstract][Full Text] [Related]
36. Successful management of unstable angina in a ravulizumab-treated patient with paroxysmal nocturnal hemoglobinuria.
Takahashi H; Mori H; Fukatsu M; Sano T; Harada K; Oikawa M; Takeishi Y; Kimura S; Ohkawara H; Shichishima T; Ikezoe T
Fukushima J Med Sci; 2022 Dec; 68(3):175-178. PubMed ID: 36130907
[TBL] [Abstract][Full Text] [Related]
37. Addition of iptacopan, an oral factor B inhibitor, to eculizumab in patients with paroxysmal nocturnal haemoglobinuria and active haemolysis: an open-label, single-arm, phase 2, proof-of-concept trial.
Risitano AM; Röth A; Soret J; Frieri C; de Fontbrune FS; Marano L; Alashkar F; Benajiba L; Marotta S; Rozenberg I; Milojevic J; End P; Nidamarthy PK; Junge G; Peffault de Latour R
Lancet Haematol; 2021 May; 8(5):e344-e354. PubMed ID: 33765419
[TBL] [Abstract][Full Text] [Related]
38. C3 inhibition with pegcetacoplan in subjects with paroxysmal nocturnal hemoglobinuria treated with eculizumab.
de Castro C; Grossi F; Weitz IC; Maciejewski J; Sharma V; Roman E; Brodsky RA; Tan L; Di Casoli C; El Mehdi D; Deschatelets P; Francois C
Am J Hematol; 2020 Nov; 95(11):1334-1343. PubMed ID: 33464651
[TBL] [Abstract][Full Text] [Related]
39. [Eculizumab in patients with paroxysmal nocturnal hemoglobinuria: a real-world study in China].
Wang LY; Hu QL; Chen M; Yang C; Han B
Zhonghua Xue Ye Xue Za Zhi; 2024 Feb; 45(2):184-189. PubMed ID: 38604796
[No Abstract] [Full Text] [Related]
40. Long-term follow-up of patients with paroxysmal nocturnal hemoglobinuria treated with eculizumab: post-marketing surveillance in Japan.
Ikezoe T; Noji H; Ueda Y; Kanda Y; Okamoto S; Usuki K; Matsuda T; Akiyama H; Shimono A; Yonemura Y; Kawaguchi T; Chiba S; Kanakura Y; Nishimura JI; Ninomiya H; Obara N
Int J Hematol; 2022 Apr; 115(4):470-480. PubMed ID: 35146630
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
